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INTRODUCTION
Acute myeloid leukemia (AML) is classified into various subtypes based on lineage differentiation and level of maturation of myeloid cells, as well as the presence of specific genetic abnormalities. One such entity is AML with the inversion (16)(p13.1q22) or t(16;16) (p13.1;q22) which is typically associated with acute myelomonocytic leukemia with abnormal eosinophils (AML-M4Eo). [1] It also may be seen in other subtypes of AML, notably AML M5. [2] AML with inv (16) is associated with a favorable prognosis. A high index of suspicion is required for the identification of inv (16) which may be overlooked because it is a subtle abnormality. We report a de novo AML M5 with abnormal eosinophils and inv (16).
CASE REPORT
A 30-year-old female presented with a two-week history of fever, cough with dyspnea and chest pain, generalized weakness, and erythematous papules over the dorsum of her right hand and bleeding per vaginum.
She had bicytopenia (Hb: 8.6 g/dl, platelet count: 19 × 10 3 /µL) and leukocytosis (white blood cell count: 294 × 10 3 /µL) with a differential count of 25% blasts, 55% monocytoid cells, 2% myelocytes, 8% neutrophils, 6% lymphocytes, 3% eosinophils, and 1% basophils. Bone marrow (BM) smears showed solidly cellular fragments and hypercellular cell trails with 81% monoblasts and promonocytes, 8% eosinophils, 8% other myeloid cells, and 3% erythroids. The eosinophils showed large, coarse, and basophilic intracytoplasmic granules [ Figure 1a ]. Sudan black B positivity was seen in ≥3% of the blasts. With dual esterase stain, 22% of cells showed positivity for nonspecific esterase, 5% showed positivity for chloroacetate esterase, and 73% were neutral [ Figure 1b ]. The blasts were periodic acid-Schiff negative. Although abnormal eosinophils are typically associated with AML M4, the morphological and cytochemical findings favored a diagnosis of AML M5. Trephine biopsy showed a hypercellular marrow with dense interstitial infiltrates of immature cells and a mild increase in eosinophil precursors [ Figure 1c and d]. Skin biopsy was consistent with leukemia cutis with a superficial dermal infiltrate of large cells with moderately pleomorphic round vesicular nuclei, prominent nucleoli, and scant cytoplasm, some of which were positive for myeloperoxidase and CD117 [ Figure 2a and b]. Flow cytometry showed expression of CD13, CD33, CD34, CD14, human leukocyte antigen-DR, CD117, and the monocytoid markers CD64 and CD11. Cytogenetic 
DISCUSSION
Among the various morphological subtypes of AML described by the World Health Organization (WHO), AML M4 and AML M5 are associated with monocytic differentiation. The differentiation between these two subtypes is based on the number of monocytoid cells (≤80% in AML M4 and ≥80% AML M5). In AML M4, the myeloid precursors account for at least 20% of the marrow population. [3] Esterase stains are useful in this regard. Nonspecific esterase identifies monocytoid cells, while specific esterase highlights myeloid cells.
AML M5 is commonly associated with bleeding manifestations as well as widespread infiltration of tissues such as the gums, skin, and central nervous system. There are two subtypes of AML M5:AML M5a (monoblastic) with ≥80% monoblasts and AML M5b (monocytic) with ≤80% monoblasts. [3] Monoblasts are large cells up to 30 µ in diameter with round to oval nuclei, delicate or lace-like chromatin, prominent nucleoli and basophilic cytoplasm. Promonocytes, the next cells in the hierarchy, which are also counted along with the monoblasts, are similar to monoblasts except that their nuclei are convoluted or indented. Monocytes are slightly smaller (up to 25 µ) and have folded nuclei, reticular chromatin, inconspicuous nucleoli, and gray vacuolated cytoplasm. [4] The pericentric inversion (16) accounts for ~5% of the cytogenetic abnormalities seen in AML and is associated with a favorable prognosis. This abnormality can occur at any age, with a median age of 35 years. The genes involved in this rearrangement are the core binding factor beta (CBF ) gene at band q22 on the long arm of chromosome 16 and the myosin heavy chain 11 gene (MYH11) at band p13.1 on its short arm. As a result of the inversion, these genes are juxtaposed to form the CBF/MYH11 fusion gene which is leukemogenic. Approximately 90% of inv(16) are associated with AML-M4Eo with other morphological subtypes accounting for the remainder. [5] The inv (16) has been reported in only 20 patients with AML M5 till date. [2] The inv (16) was the sole abnormality in 11 patients while nine had one or more additional abnormalities [ Table 1 ].
According to the WHO classification, if the inv(16) is present, a diagnosis of AML must be made irrespective of the percentage of blasts in the blood or BM. [1] The marrow in AML with inv (16) shows increased numbers of eosinophils at all stages of maturation with abnormal eosinophil precursors being seen in about 85% of cases. These abnormal eosinophilic myelocytes and promyelocytes have large, prominent, dark, almost basophilic granules which may be numerous, obscuring nuclear details. Often, these granules are admixed with the typical eosinophil granules. Other cytological abnormalities such as nuclear hyper/hypolobation and Charcot-Leyden crystals in the mature eosinophils have also been described. [5] The inv(16) is a subtle abnormality which is difficult to detect by conventional cytogenetics if the morphology of the metaphases is suboptimal; in such instances, fluorescence in situ hybridization using a probe for the CBF gene might be necessary for its identification. It is important to note that the presence of abnormal eosinophils in the BM warrants a careful search for this abnormality regardless of the morphological subtype of AML. Identification of this cytogenetic abnormality is important because of its favorable prognosis and a high rate of complete remission when treated with cytarabine.
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